Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal termsnews2025-03-18T15:01:13+00:00March 18th, 2025|Endpoints News|
Vertanical’s Phase 3 win for non-opioid painkiller; Apriori lays off 40% of staff news2025-03-17T14:58:51+00:00March 17th, 2025|Endpoints News|
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125Mnews2025-03-14T15:17:18+00:00March 14th, 2025|Endpoints News|
Ascletis’ not-so-great weight loss data; Vivace’s $35M Series Dnews2025-03-12T14:22:46+00:00March 12th, 2025|Endpoints News|
Mineralys aims to raise $250M; Coherus discloses layoffsnews2025-03-11T15:07:51+00:00March 11th, 2025|Endpoints News|
CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartisnews2025-03-07T15:05:53+00:00March 7th, 2025|Endpoints News|
Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADCnews2025-03-06T15:28:51+00:00March 6th, 2025|Endpoints News|
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffsnews2025-03-05T15:13:29+00:00March 5th, 2025|Endpoints News|
Tenaya raises about $53M; BeiGene’s PD-1 gets a first-line approvalnews2025-03-04T15:06:32+00:00March 4th, 2025|Endpoints News|
Genentech’s TNKase gets new approval; Sanofi gives up rights to oncology candidatenews2025-03-03T15:46:29+00:00March 3rd, 2025|Endpoints News|
